Gottlieb At FDA: Industry Will Look For User-Fee Deal Support, Restrained Regulations
After months of waiting on whether President Trump would pick a conventional FDA commissioner candidate or go off the beaten path, the White House appears to be taking the former approach. Trump is expected to nominate Scott Gottlieb, a George W. Bush administration FDA alum, physician and long-time conservative voice on health policy. Gottlieb will favor reduced regulatory burdens, and industry hopes he will help push forward a device user-fee reauthorization agreement.
You may also be interested in...
Scott Gottlieb was sworn in as US FDA commissioner May 11. Device-industry lobbyists say championing quick passage of user-fee reauthorization should be his near-term priority. Gottlieb is a well-known figure by some in industry, including AdvaMed chief Scott Whitaker, who served with him at HHS during the George W. Bush Administration.
FDA Commissioner nominee Scott Gottlieb's many pledges to the US Office of Government Ethics to recuse himself from decisions he might make while serving as head of the agency, cover over 35 outfits that he has worked for, is working for, or has invested in, spanning all types of medical commodities, from advanced imaging centers, to drug firms, to clinical decision software specialists and trial designers.
Former FDA Commissioner Mark McClellan talked with Medtech Insight about FDA Commissioner-nominee Scott Gottlieb, who he has worked closely with in the past at FDA and CMS. He also discussed 21st Century Cures Implementation, President Trump's budget blueprint and more.